Mirat Shah
14PUBLICATIONS
73CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (14)
Sort by Publication Date:
|Mar 30, 2026
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?Mallorie H Fiero, Mirat Shah, Laleh Amiri-Kordestani
|Oct 31, 2025
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.Mirat Shah, Mallorie H Fiero, Joyce Cheng
|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.Melanie Royce, Mirat Shah, Lijun Zhang
|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.Jennifer J Gao, Tatiana M Prowell, Haley Gittleman
|Aug 05, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.Asma Dilawari, Hui Zhang, Mirat Shah
|Jul 24, 2025
Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology.Laura A Levit, Mirat Shah, Mark J Ratain
Pageof 3
Frequent Collaborators
10 joint publications
Laleh Amiri-Kordestani
9 joint publications
Richard Pazdur
7 joint publications
William Pierce
7 joint publications
Shenghui Tang
4 joint publications
Marc Theoret
4 joint publications
Bronwyn Mixter
3 joint publications
Xin Gao
3 joint publications
Haley Gittleman
3 joint publications
Stacy S Shord
3 joint publications
Mallorie H Fiero
